It will be very interesting to determine if DUSP5 plays a wider role as a tumour suppressor in more clinically relevant mouse models of Hras or Braf-driven cancers such as pancreas, lung or intestinal tumours and to determine the extent to which it is deregulated in a wider range of human cancers. This evidence concerns the gene DUSP5 and neoplasm.